Corerx, Inc.

Form 483 issued March 6, 2020 · CLEARWATER, Florida

Inspection
Feb 24 – Mar 6, 2020
Investigator
Kayla V. Sprague
Observations
3
Pages
4
FEI number
3007209985

In short: On March 6, 2020, FDA issued a Form 483 with 3 observations to Corerx, Inc. in CLEARWATER, Florida (FEI 3007209985) after an inspection that ran Feb 24 – Mar 6, 2020. The investigator was Kayla V. Sprague. Most observations concern quality system and facilities & equipment.

At a glance

Quality system and facilities & equipment account for 2 of 3 observations.

Quality system1
Facilities & equipment1
Production1

What FDA observed

Preview: the opening words of each observation

Dashed: section inferred by FDA Intel and checked against the regulation text

  1. 01

    Investigations of a failure of a batch or any of its components to meet any of…

  2. 02

    Equipment used in the manufacture, processing, packing or holding of drug products is not of appropriate…

  3. 03

    Procedures designed to prevent objectionable microorganisms in drug products not required to be sterile are…

The full 483

Plus the full detail behind each one, exactly as FDA wrote it.

Get the full 483

This inspection in context

Questions about this 483

What did FDA find at Corerx, Inc.?

FDA listed 3 observations on this Form 483, mostly about quality system, facilities & equipment and production. The opening words of each observation are shown on this page.

Who inspected Corerx, Inc.?

Kayla V. Sprague is named on this Form 483, for the inspection of Feb 24 – Mar 6, 2020. Each investigator has a profile showing what they cite most.

When was Corerx, Inc. inspected by FDA?

The inspection ran Feb 24 – Mar 6, 2020, and the Form 483 is dated March 6, 2020.

How do I get the full Form 483 for Corerx, Inc.?

Download the original PDF from FDA Intel for $99, with no subscription. Your first Form 483 or letter is on us. You also get an invoice PDF with the order.

$99Get it free